


CLAIMS

1. A compound of the formula (I):



wherein

- 5 R^1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom,
 R^2 represents an alkyl group having from 1 to 4 carbon atoms,
 R^3 represents a hydrogen atom or a hydroxy group, and
A represents an oxygen atom or a group of the formula $-C(R^4)(R^5)-$ (in which R^4 represents a
hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R^5 represents a hydroxy
10 group or an alkoxy group having from 1 to 4 carbon atoms)
or a pharmaceutically acceptable salts thereof.
2. The compound according to Claim 1, wherein R^1 represents a halogen atom.
3. The compound according to Claim 1 and Claim 2, wherein R^2 represents an alkyl
group having from 1 to 2 carbon atoms.
- 15 4. The compound according to any one of Claims 1 to 3, wherein R^3 represents a
hydroxy group.
5. The compound according to any one of Claims 1 to 4, wherein A represents an
oxygen atom.
6. The compound of Claim 1 which is
- 20 5-chloro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}methyl)-
1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
5-chloro-6-ethyl-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}
methyl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
N-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5,6-dimet
25 hyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
5-bromo-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}methyl)-
1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
5-fluoro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl}methyl)-
1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
- 30 5-chloro-*N*-{[1-(cyclohexylmethyl)piperidin-4-yl]methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydr
opyridine-3-carboxamide;

5-chloro-*N*-({1-[(1-hydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

7. The use of a compound according to any one of claims 1 to 6 or a
5 pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a condition mediated by 5-HT₄ receptor activity.

8. The use according to claim 7, wherein a condition mediated by 5-HT₄ receptor activity represents a member selected from gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional
10 dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, and cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

15 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier for said compound.

10. A method for the treatment of a condition mediated by 5-HT₄ receptor activity, in a mammalian subject, which comprises administering to a mammal in need of such treatment a
20 therapeutically effective amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as defined in claim 9.

11. A method according to claim 10 wherein said condition mediated by 5-HT₄ receptor activity is a member selected from gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation,
25 dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, and cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.